• Publications
  • Influence
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in theExpand
  • 4,261
  • 220
  • PDF
Systematic identification of genomic markers of drug sensitivity in cancer cells
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncoverExpand
  • 1,736
  • 135
  • PDF
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependentExpand
  • 2,287
  • 128
  • PDF
The landscape of somatic copy-number alteration across human cancers
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses ofExpand
  • 2,657
  • 123
  • PDF
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, inExpand
  • 2,833
  • 119
Trastuzumab emtansine for HER2-positive advanced breast cancer.
BACKGROUND Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with theExpand
  • 2,079
  • 94
  • PDF
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
BACKGROUND Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cellExpand
  • 1,531
  • 90
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Cells in Transit(ion) Epithelial-mesenchymal transition (EMT) is a developmental program that converts adherent epithelial cells to a migratory mesenchymal state. This cell-fate change has beenExpand
  • 1,237
  • 69
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
BACKGROUND Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTORExpand
  • 1,520
  • 65
  • PDF
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Activation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTORC1-mediated inhibition of upstream signaling. We now show that AKT inhibition induces the expression andExpand
  • 802
  • 56
  • PDF